本帖最后由 老马 于 2012-1-13 21:20 编辑
0 C8 q T) g- j3 K5 G' o1 l' Q/ z: `" _5 i: z/ e
爱必妥和阿瓦斯丁的比较& k$ j- `3 R. } E3 U# @+ v
8 U2 @) t" C. z) k" S/ G# Q' o
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/; u; D1 h% u, o$ C5 E& d/ b* F
; ?+ J# L6 _- K- g; d
4 e* A- i$ h- O5 l/ m) g5 `7 khttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
B! S0 i/ G! A8 S7 x# j==================================================3 b( [: k% U0 w# j: K9 @( i
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
+ M: ?9 L% y! o7 p9 ~Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.6 o" l, j5 x4 J9 C
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.6 L2 Q' }9 b1 O9 i& A5 S+ o
|
显身卡
" C2 @9 \+ H5 S, m8 f8 F
